spc2996
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00285103)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- spc2996
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00285103 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2005 | Santaris Pharma A/S, University of Lyon |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Santaris Pharma A/S | For profit | 1 | 1 | 1 | 2005 |
| University of Lyon | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1